Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Phacoemulsification two years after central descemetorrhexis without corneal graft for Fuchs' endothelial dystrophy

Poster Details

First Author: R.Nosé USA

Co Author(s):    Y. Lu   R. Pineda II                 

Abstract Details


To report a case of a 60 year-old woman with Fuchs endothelial dystrophy who underwent phacoemulsification for moderate nuclear sclerosis two years after central Descemet membrane stripping without placement of a corneal graft.


Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA


A retrospective chart review and report of surgical outcome was performed. Preoperative pachymetry was 490 microns, and recent specular microscopy central endothelial cell count was 1471 cells/mm2. using the Nidek CEM-530 (Nidek Co., Japan). Phacoemulsification was carried out with the Alcon Centurion Vision System (Alcon, Fort Worth, Texas, USA), using a softshell technique with a divide and conquer nuclear disassembly. Standard coaxial irrigation and aspiration was performed. The AMO Tecnis ZCB00 (Abbott Medical Optics, Santa Ana, CA, USA) +23.0 diopter lens was placed in the capsular bag without complications.


Patient had mild central corneal edema which resolved by one week. Best corrected vision by 1 month was 20/20, and intended target refraction was accurate. Endothelial cell loss was less than 10% after one month.


We report the first known case of phacoemulsification following central descemetorrexis without endothelial corneal transplantation for Fuchs endothelial dystrophy. Phacoemulsification resulted in a minimal affect on endothelial cell count, with only mild clinical postoperative corneal edema which resolved by one week with a good visual outcome. As novel strategies for endothelial disorders progress, understanding the impact of phacoemulsification on endothelial repopulation will be an important consideration.

Financial Disclosure:


Back to Poster listing